All News

While you're making plans for the 2009 AUA annual meeting (April 25-30), be sure to pencil in some time to savor the wealth of recreational, cultural, entertainment, and dining opportunities offered in this west coast (of Lake Michigan) city.

"I don't subscribe to the theory that reps who come to our office have a tremendous impact on what we do anyway."

Products and services from manufacturers who are exhibiting at the American Urological Association meeting in Chicago.

Drugs and devices in the pipeline

In laboratories and surgical suites, urologists at Johns Hopkins University, Baltimore, are breaking new ground in prostate cancer research as well as setting improved quality standards of care.

Experienced clinicians, a broad range of treatment options, extensive and well-funded research, a large and comprehensive patient database, and a strong emphasis on collaboration make the Mayo Clinic's department of urology a Clinical Center of Excellence for the treatment of prostate cancer.

The Memorial Sloan-Kettering Cancer Center Sidney Kimmel Center for Prostate and Urologic Cancers is striving to defeat metastatic prostate cancer through aggressive efforts in prevention, detection, diagnosis, research, and treatment.

Cleveland Clinic has a history of pioneering innovation and leading-edge research in urology. Prostate cancer is no exception.

The purpose of the Clinical Centers of Excellence series is to recognize those institutions that bring something extra to the specialty, whether through research, patient care, community outreach, or all of these areas.

In patients with bladder cancer, tumor characteristics at presentation are less favorable in women and African-Americans versus Caucasian men, according to a study by researchers at the University of Rochester, New York.

By losing just 8% of their total body weight, overweight and obese women can significantly reduce the frequency of urinary incontinence episodes, according to results of a multicenter trial.

Using a relatively novel approach to identify microalterations differentiating benign prostatic disease from clinically localized prostate cancer and its progression to metastatic disease, researchers at the University of Michigan have identified a series of metabolites that they believe hold promise for use as biomarkers of tumor aggressiveness and invasiveness.

Focal therapy for prostate cancer has been surrounded by controversy due to the multifocal nature of the disease. Emerging evidence for a biologically dominant or index tumor, however, has the potential to shift the paradigm to focal therapy in carefully selected patients, according to experts speaking at the Medical Innovation Summit at Cleveland Clinic.

A visit to this third-largest U.S. city puts you at the heart of a gastronomic paradise.

National Cancer Institute Specialized Program of Research Excellence (SPORE) in Prostate Cancer

Clinical Centers of Excellence - Prostate Cancer: Memorial Sloan-Kettering Cancer Center by the numbers

Number of patients treated/procedures performed per year – 1,200 radical prostatectomies performed in 2008.

Clinical Centers of Excellence - Prostate Cancer: Mayo Clinic by the numbers

Johns Hopkins' James Buchanan Brady Urological Institute in fiscal 2008 received $9 million in grants from the National Cancer Institute.

Clinical Centers of Excellence - Prostate Cancer: Johns Hopkins University by the numbers

Clinical Centers of Excellence – Prostate Cancer: Cleveland Clinic – Selection criteria

Clinical Centers of Excellence – Prostate Cancer: Cleveland Clinic by the numbers

The National Association For Continence (NAFC) announced Roger Dmochowski, MD, as the latest recipient of its Rodney Appell Continence Care Champion award.

UCLA has launched a patient-centered institute dedicated to developing therapies for the treatment of kidney, bladder, testicular, and prostate cancers.

Novasys Medical, Inc. (Newark, CA) recently announced that Noridian Administrative Services, LLC, a regional Medicare carrier, is now covering the non-surgical Renessa treatment for women with stress urinary incontinence.

New data analyses from a phase III clinical trial suggest favorable results using an investigational form of immunotherapy in men with prostate cancer.

Researchers have reported positive preliminary results from a phase II study of AT-101 in combination with docetaxel (Taxotere) and prednisone in men with docetaxel-refractory, castrate-resistant prostate cancer.